迪安诊断(300244) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥2,629,101,734.09, a decrease of 13.52% compared to the same period last year[5] - Net profit attributable to shareholders was ¥46,427,604.81, down 21.46% year-on-year, while the net profit excluding non-recurring gains and losses was ¥44,787,340.40, a decrease of 23.94%[5] - For the first nine months of 2025, the company achieved a total revenue of ¥7,565,586,728.42, representing an 18.28% decline year-on-year[9] - Total operating revenue for the current period is ¥7,565,586,728.42, a decrease of 18.3% from ¥9,258,110,867.57 in the previous period[21] - Net profit for the current period is ¥182,010,837.30, a decline of 39.9% compared to ¥302,683,796.72 in the previous period[22] - Earnings per share (basic) for the current period is ¥0.0928, down from ¥0.2118 in the previous period[22] - The company’s total profit before tax is ¥276,089,133.22, down from ¥424,171,620.41 in the previous period, representing a decline of 34.8%[22] - The company’s total comprehensive income for the current period is ¥182,010,837.30, compared to ¥302,682,117.22 in the previous period[22] Cash Flow and Assets - The company reported a significant increase in net cash flow from operating activities, reaching ¥871,715,623.10, a rise of 1508.33% compared to the previous year[9] - Operating cash flow for the current period is ¥871,715,623.10, a significant increase from ¥54,200,047.93 in the previous period, reflecting a strong operational performance[24] - Total cash inflow from operating activities decreased to ¥8,468,610,339.97 from ¥9,601,233,221.75, indicating a decline of approximately 11.8% year-over-year[24] - Cash outflow from operating activities also decreased to ¥7,596,894,716.87 from ¥9,547,033,173.82, resulting in a reduction of about 20.4%[24] - The ending cash and cash equivalents balance is ¥1,346,814,696.43, a slight decrease from ¥1,352,553,738.03 in the previous period[25] - The company’s cash flow from operating activities reflects a robust operational strategy despite a decrease in total cash inflows[24] Shareholder Information - Total number of common shareholders at the end of the reporting period was 45,695[12] - The largest shareholder, Chen Haibin, holds 26.31% of shares, totaling 164,438,933 shares, with 76,460,000 shares pledged[12] - The company repurchased 13,880,000 shares, accounting for 2.22% of the total share capital[13] - The number of shares held by the top ten unrestricted shareholders totaled 100,000,000 shares[13] Asset and Liability Management - Total assets at the end of the reporting period were ¥14,765,016,764.23, a decrease of 6.47% from the previous year[5] - The company's total current assets decreased from CNY 11,902,542,869.23 to CNY 11,040,261,948.58, a decline of approximately 7.24%[18] - Cash and cash equivalents decreased from CNY 1,830,317,273.55 to CNY 1,372,146,968.42, a reduction of about 25%[18] - Accounts receivable decreased from CNY 7,258,897,680.33 to CNY 6,735,971,949.60, a decline of approximately 7.2%[18] - Total liabilities amount to ¥6,090,797,605.65, a decrease from ¥7,018,794,162.32 in the previous period[20] - Total equity is ¥8,674,219,158.58, down from ¥8,767,189,572.23 in the previous period[20] - The company’s long-term borrowings decreased to ¥1,348,014,472.00 from ¥1,593,720,736.00, a reduction of 15.4%[20] Operational Developments - The company added 12 new precision centers in the first three quarters, bringing the total to 102, with related business growth of 11.25%[10] - The company signed 1,504 new clients, further increasing its market share[10] - The company is advancing its AI products and digital solutions, collaborating with partners like Alibaba and Huawei Cloud, and has become a key player in the trusted data space in Hangzhou[10] - Financial expenses decreased by 36.56% during the reporting period, reflecting improved internal management efficiency[10] Research and Development - The company reported a decrease in research and development expenses to ¥169,463,374.03 from ¥225,278,980.27, a reduction of 24.8%[21]